Selection of 5 products from
£14.35 to £20.65
Simparica™ (sarolaner) Chewables are safe, monthly flea and tick protection for dogs that start working fast and remain effective all month long.
Simparica™ starts killing fleas within 3 hours and ticks within 8 hours, and it keeps going strong for 35 days without losing effectiveness at the end of the month.
Proven persistent protection against fleas and ticks.
Simparica is effective against fleas and ticks, even on day 35! You can count on Simparica to do the following:
Simparica chewable tablets are brown, square tablets with 5, 10, 20, 40 or 80 embossed on one side. Each tablet contains:
|Simparica chewable tablets||sarolaner (mg)|
|for dogs 1.3 - 2.5 kg||5|
|for dogs >2.5 - 5 kg||10|
|for dogs >5 - 10 kg||20|
|for dogs >10 - 20 kg||40|
|for dogs >20 - 40 kg||80|
For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis) in dogs. Simparica has immediate and persistent flea killing activity against new infestations for at least 5 weeks. Simparica can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus). Simparica has immediate and persistent tick killing activity for at least 5 weeks. For the treatment of sarcoptic mange (Sarcoptes scabiei). Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
For oral use. Tablets can be administered with or without food. Simparica should be administered at a dose of 2-4 mg/kg bodyweight in accordance with the following table:
|Bodyweight (kg)||Tablet strength (mg sarolaner)||Number of tablets to be administered|
|1.3 - 2.5||5||One|
|>2.5 - 5||10||One|
|>5 - 10||20||One|
|>10 - 20||40||One|
|>20 - 40||80||One|
|>40||Appropriate combination of tablets|
Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg. Simparica tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided. Treatment schedule: For optimal control of flea and tick infestations, Simparica should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations. For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded. In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. The safety of Simparica has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects. Use only according to the benefit/risk assessment by the responsible veterinarian. Simparica has been administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum dose of 4 mg/kg. In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum dose and convulsions at 5 times the maximum dose. All dogs recovered without treatment. Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed. User warnings Wash hands after handling the product. The accidental ingestion of the product may potentially result in adverse effects, such as transient excitatory neurological signs. To prevent children from accessing the product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should then be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.
Simparica does not require any special storage conditions. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Keep out of the sight and reach of children. For animal treatment only.
Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines. For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration. For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration. Ticks on the animal prior to administration are killed within 24 hours. Simparica kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access. In addition, in laboratory studies, sarolaner was shown to be active against other tick species such as Dermacentor variabilis, Ixodes scapularis, Amblyomma americanum, Amblyomma maculatum as well as the mite species Demodex canis and Otodectes cynotis. During clinical field trials, no interactions between Simparica chewable tablets for dogs and routinely used veterinary medicinal products were observed. In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated). Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.
All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.
Below are some recent questions we've received regarding Simparica Flea & Tick Tablets, including answers from our team.Ask Your Own Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VioPoints are a way for us to say thank you for purchasing from VioVet.
You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VioPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.